Effectiveness Of Pharmaceutical Therapy Of ADHD (Attention Deficit Hyperactivity Disorder) In Adults – Health Technology Assessment

This research examined how well prescription medications work for treating ADHD (Attention-Deficit/Hyperactivity Disorder) in adults. ADHD is a brain condition that causes problems with attention, hyperactivity, and impulsiveness that begins in childhood but can continue into adulthood, significantly impacting quality of life and daily functioning.

Researchers analyzed 19 studies to evaluate the effectiveness and costs of ADHD medications in adults. They found that stimulant medications containing methylphenidate (like Ritalin) and amphetamines, as well as a non-stimulant called atomoxetine, all reduced ADHD symptoms more effectively than placebo pills. The success rates ranged from 17-60% for people taking medication versus only 7-42% for those taking placebo.

The study also revealed that adults with untreated ADHD face higher healthcare costs, spending an average of $1,262-$1,673 annually on medical expenses (adjusted to approximately 1,270-1,619 euros in 2009). This suggests that effective treatment could potentially reduce long-term healthcare costs. However, the researchers noted that stimulant medications may affect a person's ability to drive or participate in certain activities.

From a metabolic health perspective, untreated ADHD can lead to poor lifestyle habits, irregular eating patterns, and difficulty maintaining exercise routines—all factors that impact long-term health and longevity. In clinical practice, this research supports the use of FDA-approved ADHD medications as an evidence-based treatment option for adults, though the specific medication availability mentioned in this German study may differ from current U.S. prescribing practices.